MRTX-1257 is a selective, irreversible, covalent and orally active KRAS G12C inhibitor, with an IC 50 of 900 pM for KRAS dependent ERK phosphorylation in H358 cells.
性状
Solid
IC50 & Target[1][2]
KRAS(G12C)
体内研究(In Vivo)
MRTX-1257 (1 mg/kg, 3 mg/kg, 10 mg/kg, 30 mg/kg and 100 mg/kg, orally, daily for 30 days) shows rapid tumor growth inhibition at all dose groups in MIA PaCa-2 G12C Xenograft model in mice.
MRTX-1257 shows sustained regression at 3,10, 30, and 100 mg/kg dose groups.
MRTX-1257 dosed of 100 mg/kg daily leads to complete responses that are maintained >70 days after cessation of treatment. has not independently confirmed the accuracy of these methods. They are for reference only.
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
-20°C, stored under nitrogen In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
参考文献
[1]. Matthew et al. Structure-Based Drug Discovery of MRTX1257, a Selective, Covalent KRAS G12C Inhibitor with Oral Activity in Animal Models of Cancer.
溶解度数据
In Vitro: DMSO : 55 mg/mL (97.22 mM; Need ultrasonic)配制储备液